Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

Exclusion Criteria

• •1. History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix;
• •2. Confirmed that apatinib and/or its accessories allergy;
• •3. Subjects with poor-controlled arterial hypertension (systolic blood pressure\> 140 mmHg and diastolic blood pressure \> 90 mm Hg) despite standard medical management;
• •4. Serious cardiovascular disease: Ⅱ-level myocardial ischemia or myocardial infarction, arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms); III \~ IV level cardiac function insufficiency, or echocardiography showed that left ventricular ejection fraction (LVEF \< 50%);
• •5. Patients with positive urinary protein (urine protein detection of 2 or more, or 24 hour urine protein \>1.0g);
• •6. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
• •7. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy result;
• •8. Abnormal Coagulation (INR\>1.5、APTT\>1.5 UNL), with tendency of bleed;
• •9. With psychotropic drug abuse history and can't get rid or with mental disorder patients;
• •10. Less than 4 weeks from the last clinical trial;
• •11. According to the researcher's judgment, with other serious diseases which harm to patient safety or affect patients complete the study;
• •12. Evidence of central nervous system(CNS) metastasis;
• •13. Pregnant or lactating women;
• •14. Other conditions regimented at investigators' discretion.